Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 193

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 193
---
 at the Special Meeting other than as described in this Circular and Proxy Statement.

Adjournments or Postponements

Subject to
the terms of the Agreement, the Special Meeting may be adjourned from time to time.

Future Shareholder Proposals

If the Arrangement is consummated, we will not have public shareholders and there will be no public participation in any future meeting of
shareholders. However, if the Arrangement is not completed, we expect to hold a 2026 Annual Meeting of Shareholders. In addition to complying with the advanced notice provisions included in our articles, which required that nominating
shareholders’ notice be received no later than 30 days before the 2026 Annual Meeting of Shareholders, a Shareholder who would like to have a proposal considered for inclusion in our 2026 proxy statement must have submitted the proposal in
accordance with the procedures outlined in Rule 14a-8 of the Exchange Act. Shareholder proposals submitted pursuant to SEC rules under the Exchange Act for inclusion in the 2026 proxy materials must be
received by us no later than December 30, 2025. SEC rules set standards for eligibility and specify the types of shareholder proposals that may be excluded from a proxy statement. In addition, shareholders who would like to solicit proxies in
support of director nominees other than our nominees must provide in their notice any additional information required by Rule 14a-19(b) under the Exchange Act.

The QBCA also sets out the requirements for a valid proposal and provides for the rights and obligations of the Company and the submitter upon
a valid proposal being made. Proposals submitted under the applicable provisions of the QBCA that a shareholder intends to present at the 2026 Annual Meeting of Shareholders and wishes to be considered for inclusion in the Company’s proxy
statement and form of proxy relating to such annual meeting must be received at least three months before the anniversary of the Company’s last annual general meeting. Such proposals must also comply with all applicable provisions of the QBCA
and the regulations thereunder.

Shareholder proposals should be addressed to Repare Therapeutics Inc., 7171 Frederick-Banting, Building
2, Suite 270, St-Laurent, Québec, Canada.

Householding of Special Meeting Materials

The SEC has adopted rules that permit companies and intermediaries, such as brokers and banks, to satisfy the delivery requirements for
information circular and proxy statements with respect to two or more Shareholders sharing an address by delivering a